3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
2
Breast Neoplasms
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
pembrolizumab
23
Gemcitabine
14
Carboplatin
10
Nivolumab
9
Cyclophosphamide
9
olaparib
8
Specimen Handling
8
Paclitaxel
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
6
fludarabine
5
Standard of Care
5
Irinotecan
5
Ipilimumab
5
Docetaxel
5
Cisplatin
5
Capecitabine
5
Biopsy
5
sargramostim
4
pertuzumab
4
palbociclib
4
enzalutamide
4
durvalumab
4
atezolizumab
4
aldesleukin
4
Taxes
4
Oxaliplatin
4
Fluorouracil
4
Erlotinib Hydrochloride
4
Early Intervention, Educational
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Motivational Interviewing
×
Genitourinary
×
Clear all
NCT05162846
2026-03-09
MiGHT
University of Michigan Rogel Cancer Center
Phase NA
Completed
831 enrolled